A549 HLA Panel Cell Lines

Tested for Mycoplasma, bacterial and fungal content, post-freeze viability, and short terminal repeat (STR) analysis for cell line identification.

Derived from a 58 year old Caucasian male. The cells can synthesise lecithin utilising the cytidine diphosphocholine pathway. Occasional cells may also contain inclusion bodies although they are not known to carry any human pathogen.

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Unlike wild type A549 cells, which express multiple HLA subtypes, the A549 HLA panel cell lines express individual MHC Class I HLA subtypes. These monoallelic HLA cell lines can be used to study peptide binding and presentation in the context of individual HLA subtypes. The panel can also be used to develop cell-based assays to evaluate candidate cancer immunotherapies and identify tumor-specific neoantigens.

The STR profile of these cell lines match that of its parental cell line - ECACC catalog number 86012804.

This product is a panel of eleven (11) genetically modified cell lines targeting MHC Class I HLA molecules in an A549 lung carcinoma parental cell line background.  The full HLA panel consists of a Beta-2 microglobulin (β2M) knockout cell line and an additional ten (10) monoallelic HLA expression cell lines.  

CompoZr^® Zinc Finger Nuclease (ZFN) technology was used to generate the β2M knockout cell line, which does not express endogenous cell surface MHC Class I HLA molecules (HLA-A or HLA-B) as measured by fluorescence-activated cell sorting (FACS).  

MISSION^® lentivirus was used to generate the ten (10)  monoallelic HLA cell lines, which express individual HLA-A or HLA-B subtypes on the cell surface via a β2M:HLA fusion protein as described in Nature Biotechnology 35, 765-772, (2017) and as demonstrated via FACS analysis.  

CompoZr is a registered trademark of Merck KGaA, Darmstadt, Germany

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

HLA003A-1VL: A549 B2M KO Cells
HLA003B-1VL: A549 HLA-A*02:01 Cells
HLA003C-1VL: A549 HLA-A*01:01 Cells
HLA003D-1VL: A549 HLA-A*03:01 Cells
HLA003E-1VL: A549 HLA-A*11:01 Cells
HLA003F-1VL: A549 HLA-A*24:02 Cells
HLA003G-1VL: A549 HLA-B*15:10 Cells
HLA003H-1VL: A549 HLA-B*07:02 Cells
HLA003I-1VL: A549 HLA-B*08:01 Cells
HLA003J-1VL: A549 HLA-B*35:01 Cells
HLA003K-1VL: A549 HLA-B*40:01 Cells